{"id":1020264,"date":"2026-11-12T09:07:55","date_gmt":"2026-11-12T14:07:55","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/"},"modified":"2026-11-12T09:07:55","modified_gmt":"2026-11-12T14:07:55","slug":"alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/","title":{"rendered":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">MELBOURNE, Australia and SAN FRANCISCO, Nov.  12, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=N0YsqzJm6jVHAlIvGXIuv2engsAffxhS1p_hi0sSGw__A9hFcwRWumZS8GWnCWW5SBoyiW0x6HuYC5j3LfrpbALHHyfh4azZFeoN00pCtAw=\" rel=\"nofollow\" target=\"_blank\">Alterity Therapeutics<\/a> (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0virtual Bell Potter Healthcare Conference on Thursday, November 19, 2026 at 12:00 p.m. AEDT.<\/p>\n<p align=\"justify\">A link to the archived webcast will be available after the event and can be accessed on Alterity Therapeutics website under the Investors section: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XfCLtNp4T0SdV6eKnpsKi6RggvnDS7xzd1Qfxu3Be9HQGzseNbDwMyM5-0WCvqQd3i3O1SybK7-v0ObfqnjU9PcX7QE2igPpw23mKmE9k5tH2zhhwpdLwJ3TAE60imwU8VsZfgfn-GIPwA9FHX5Y8w==\" rel=\"nofollow\" target=\"_blank\">Events and Presentations<\/a>. <\/p>\n<p><strong>About Alterity Therapeutics Limited <\/strong><\/p>\n<p align=\"justify\">Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson\u2019s disease and related disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy (MSA), a rare and rapidly progressive neurodegenerative disease without an approved treatment. ATH434, the Company\u2019s lead asset, demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QuimSgvUGbVtA9mH6900D_QqWEaFSUj1BUZt7ZdwkDoK5YW2QUbhbmnquN1VfZQVe8hGa3RHpJ-YTm4Nhsr_ZC4aeyF4xWeMhrpD5MwpvjE=\" rel=\"nofollow\" target=\"_blank\">https:\/\/alteritytx.com<\/a>. <\/p>\n<p><strong>Authorisation &amp; Additional information<\/strong><\/p>\n<p>This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Elyse Shapiro<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aO79abib1x1kivrM8wbS10_fBguUSBrco3UyqsrEsLlf5a_Pk5v5v4a53kCtu24aUmDociBb9U10Ktb6RZXMuY59B0YzDWSTAIR20E85gCw=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><\/p>\n<p>Remy Bernarda<br \/>Investor Relations Advisory Solutions<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aO79abib1x1kivrM8wbS1zWtiPxZKHJwKNcY_UTfnfeIbpqssK4u7DiGJKy0kiftwOTLbgcvhhTJkylj_w89OGKlar8uBf0S2b3rmtRDXu0=\" rel=\"nofollow\" target=\"_blank\">ir@alteritytx.com<\/a><br \/>+1 (415) 203-6386<\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Melissa Tempra<br \/>NWR Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Mv0Ta9nzfF9HuWXZgwrT8xBDcY-VbW7DY2pOyK6IZHmUVTIB3AIkczju8WyHR4m-Z-UvWQVD6vHFgRAyH6IKO07_TGB_Tlm1DRnin1gS8zD-VlTJJS6YjQERMmA0LIv9s4cZePz3Mb5rTeS83zIOOw==\" rel=\"nofollow\" target=\"_blank\">melissa@nwrcommunications.com.au<\/a><\/p>\n<p>Casey McDonald<br \/>Tiberend Strategic Advisors, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UPVbItlk_wCKCBRwKRVLtZ8nLEoEIVMxdVkUSlH-NHyJbFw6SP0QgGzyu7RQEqT-RUhhABgyf1G44zpVq1cxHZJeN-GW5Akill-_aEwu2EA=\" rel=\"nofollow\" target=\"_blank\">cmcdonald@tiberend.com<\/a><br \/>+1 (646) 577-8520<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MTcwNzgwYTMtOTc5OS00NTNlLTllZDgtNTY1MjY0ZDQ4ZWNkLTEyNjgyNjItMjAyNi0xMS0xMi1lbg==\/tiny\/ALTERITY-THERAPEUTICS-LIMITED.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0virtual Bell Potter Healthcare Conference on Thursday, November 19, 2026 at 12:00 p.m. AEDT. A link to the archived webcast will be available after the event and can be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson\u2019s disease &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020264","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0virtual Bell Potter Healthcare Conference on Thursday, November 19, 2026 at 12:00 p.m. AEDT. A link to the archived webcast will be available after the event and can be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson\u2019s disease &hellip; Continue reading &quot;Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-12T14:07:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference\",\"datePublished\":\"2026-11-12T14:07:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/\",\"name\":\"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\",\"datePublished\":\"2026-11-12T14:07:55+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk","og_description":"MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) &#8212; Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (\u201cAlterity\u201d or \u201cthe Company\u201d), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced\u00a0that David Stamler, M.D., Chief Executive Officer, will present at the\u00a0virtual Bell Potter Healthcare Conference on Thursday, November 19, 2026 at 12:00 p.m. AEDT. A link to the archived webcast will be available after the event and can be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living\u00a0with neurodegenerative diseases. The Company is focused on developing disease modifying therapies for Parkinson\u2019s disease &hellip; Continue reading \"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-12T14:07:55+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference","datePublished":"2026-11-12T14:07:55+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/","name":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=","datePublished":"2026-11-12T14:07:55+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NTU3MiM3OTYwMjA0IzIyNTY3MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alterity-therapeutics-to-present-at-the-virtual-bell-potter-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alterity Therapeutics to Present at the Virtual Bell Potter Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020264","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020264"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020264\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020264"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020264"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020264"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}